Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 5.0x - 5.5x | 5.2x |
| Selected Fwd Revenue Multiple | 4.8x - 5.3x | 5.1x |
| Fair Value | ₩4,207 - ₩4,816 | ₩4,511 |
| Upside | 38.8% - 59.0% | 48.9% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| HansBiomed Corporation | A042520 | KOSDAQ:A042520 |
| Kangstem Biotech Co., Ltd. | A217730 | KOSDAQ:A217730 |
| KoBioLabs, Inc | A348150 | KOSDAQ:A348150 |
| Dx & Vx Co., Ltd. | A180400 | KOSDAQ:A180400 |
| Naturalendo Tech Co., Ltd. | A168330 | KOSDAQ:A168330 |
| CORESTEMCHEMON Inc. | A166480 | KOSDAQ:A166480 |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| A042520 | A217730 | A348150 | A180400 | A168330 | A166480 | |||
| KOSDAQ:A042520 | KOSDAQ:A217730 | KOSDAQ:A348150 | KOSDAQ:A180400 | KOSDAQ:A168330 | KOSDAQ:A166480 | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | 3.9% | 6.7% | 159.9% | 42.6% | 27.6% | 3.4% | ||
| 3Y CAGR | 11.1% | 11.6% | 186.9% | 65.6% | 14.9% | -1.7% | ||
| Latest Twelve Months | 3.0% | 30.3% | 106.3% | -17.7% | 18.5% | -14.5% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | -6.9% | -201.3% | -337.3% | -44.9% | -42.2% | -37.6% | ||
| Prior Fiscal Year | -5.3% | -126.1% | -55.7% | -37.5% | -21.8% | -58.6% | ||
| Latest Fiscal Year | 0.8% | -179.3% | -10.1% | -63.6% | -16.9% | -76.6% | ||
| Latest Twelve Months | -0.9% | -153.4% | -10.1% | -63.6% | -16.9% | -76.6% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 1.40x | 7.42x | 1.23x | 3.44x | 2.42x | 3.91x | ||
| EV / LTM EBIT | -153.3x | -4.8x | -12.2x | -5.4x | -14.3x | -5.1x | ||
| Price / LTM Sales | 1.08x | 9.43x | 1.59x | 2.70x | 2.36x | 2.57x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | 1.23x | 2.42x | 7.42x | |||||
| Historical EV / LTM Revenue | 3.91x | 6.30x | 12.76x | |||||
| Selected EV / LTM Revenue | 4.98x | 5.24x | 5.50x | |||||
| (x) LTM Revenue | 28,762 | 28,762 | 28,762 | |||||
| (=) Implied Enterprise Value | 143,158 | 150,692 | 158,227 | |||||
| (-) Non-shareholder Claims * | (38,585) | (38,585) | (38,585) | |||||
| (=) Equity Value | 104,573 | 112,107 | 119,642 | |||||
| (/) Shares Outstanding | 24.4 | 24.4 | 24.4 | |||||
| Implied Value Range | 4,292.78 | 4,602.08 | 4,911.38 | |||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 4,292.78 | 4,602.08 | 4,911.38 | 3,030.00 | ||||
| Upside / (Downside) | 41.7% | 51.9% | 62.1% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A042520 | A217730 | A348150 | A180400 | A168330 | A166480 | |
| Enterprise Value | 112,767 | 94,758 | 81,583 | 116,890 | 53,919 | 112,396 | |
| (+) Cash & Short Term Investments | 5,539 | 25,821 | 55,830 | 11,214 | 260 | 4,501 | |
| (+) Investments & Other | 5,118 | 7,548 | 2,560 | 8,612 | 872 | 3,740 | |
| (-) Debt | (36,398) | (7,610) | (16,540) | (42,784) | (2,908) | (46,826) | |
| (-) Other Liabilities | (13) | 0 | (17,558) | (2,384) | 332 | 0 | |
| (-) Preferred Stock | 0 | 0 | (94) | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 87,013 | 120,516 | 105,781 | 91,547 | 52,475 | 73,811 | |
| (/) Shares Outstanding | 13.0 | 56.1 | 19.4 | 49.2 | 31.6 | 24.4 | |
| Implied Stock Price | 6,700.00 | 2,150.00 | 5,460.00 | 1,860.00 | 1,662.00 | 3,030.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 6,700.00 | 2,150.00 | 5,460.00 | 1,860.00 | 1,662.00 | 3,030.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |